S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
What to watch for as China's major political meeting of the year gets underway
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption

Viridian Therapeutics (VRDN) Stock Price, News & Analysis

$19.89
+1.18 (+6.31%)
(As of 03/1/2024 ET)
Today's Range
$18.88
$20.24
50-Day Range
$17.74
$23.82
52-Week Range
$10.93
$33.31
Volume
1.48 million shs
Average Volume
808,632 shs
Market Capitalization
$1.25 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.10

Viridian Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
91.6% Upside
$38.10 Price Target
Short Interest
Healthy
12.35% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Viridian Therapeutics in the last 14 days
Based on 35 Articles This Week
Insider Trading
Acquiring Shares
$10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.25) to ($4.10) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.53 out of 5 stars

Medical Sector

304th out of 950 stocks

Medical Laboratories Industry

10th out of 21 stocks


VRDN stock logo

About Viridian Therapeutics Stock (NASDAQ:VRDN)

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-002 and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-004, a discovery-stage therapeutic antibody program for rare disease; and VRDN-005 and VRDN-006, a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. is headquartered in Waltham, Massachusetts.

VRDN Stock Price History

VRDN Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Viridian Therapeutics GAAP EPS of -$1.35
VRDN Mar 2024 30.000 put
BTIG Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
See More Headlines
Receive VRDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viridian Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/03/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:VRDN
Employees
86
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.10
High Stock Price Target
$46.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+91.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-129,870,000.00
Net Margins
-75,711.48%
Pretax Margin
-75,711.46%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$3.75 per share

Miscellaneous

Free Float
61,870,000
Market Cap
$1.25 billion
Optionable
Optionable
Beta
1.08
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Stephen F. Mahoney J.D. (Age 53)
    MBA, CEO, President & Director
  • Dr. Eric N. Olson Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow M.D. (Age 79)
    Ph.D., Co-Founder & Member of the Scientific Advisory Board
  • Dr. Marvin H. Caruthers Ph.D. (Age 84)
    Co-Founder & Scientific Advisory Board Member
  • Mr. Vahe Bedian Ph.D.
    Co-Founder & Scientific Advisor
  • Mr. Seth Harmon
    Senior VP of Finance and Accounting, Principal Financial & Accounting Officer
  • Mr. Thomas W. Beetham J.D. (Age 55)
    MBA, Chief Operating Officer
  • Mr. John A. Jordan
    Vice President of Investor Relations & Corporate Communications
  • Mr. Anthony Casicano (Age 48)
    Chief Commercial Officer
  • Dr. Thomas A. Ciulla M.B.A. (Age 59)
    M.D., Chief Medical Officer














VRDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Viridian Therapeutics stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRDN shares.
View VRDN analyst ratings
or view top-rated stocks.

What is Viridian Therapeutics' stock price target for 2024?

10 brokers have issued 1 year price targets for Viridian Therapeutics' shares. Their VRDN share price targets range from $30.00 to $46.00. On average, they expect the company's share price to reach $38.10 in the next twelve months. This suggests a possible upside of 91.6% from the stock's current price.
View analysts price targets for VRDN
or view top-rated stocks among Wall Street analysts.

How have VRDN shares performed in 2024?

Viridian Therapeutics' stock was trading at $21.78 on January 1st, 2024. Since then, VRDN stock has decreased by 8.7% and is now trading at $19.89.
View the best growth stocks for 2024 here
.

When is Viridian Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VRDN earnings forecast
.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.37. The firm had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.15 million. Viridian Therapeutics had a negative trailing twelve-month return on equity of 121.80% and a negative net margin of 75,711.48%. Viridian Therapeutics's revenue was down 31.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.13) EPS.

Who are Viridian Therapeutics' major shareholders?

Viridian Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.71%), Commodore Capital LP (3.66%), Perceptive Advisors LLC (3.29%), Vestal Point Capital LP (1.90%), Octagon Capital Advisors LP (1.18%) and Kynam Capital Management LP (1.16%). Insiders that own company stock include Barrett Katz, Fairmount Funds Management Llc, Jonathan Violin, Lara Meisner, Life Sciences Public F Frazier and Scott Dunseth Myers.
View institutional ownership trends
.

How do I buy shares of Viridian Therapeutics?

Shares of VRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRDN) was last updated on 3/3/2024 by MarketBeat.com Staff